# US Gene Expression Analysis Market > US Gene Expression Analysis Market Research Report: Size, Share, Trend Analysis By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations, Others), By Product (Consumables, Instruments), By Applications (Drug Discovery, Diagnosis, Research) and By Service (Gene Expression Profiling Services, Sequencing Services, Bioinformatics Solutions, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.31% - **2024:** $ 1,140 Million - **2025:** $ 1,257.53 Million - **2035:** $ 3,356.2 Million - **Key Players:** Thermo Fisher Scientific (US), Illumina (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Qiagen (DE), Roche (CH), PerkinElmer (US), Merck KGaA (DE), Takara Bio (JP) **Report ID:** MRFR/LS/18106-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-gene-expression-analysis-market-19653 --- ## Market Summary ## **US Gene Expression Analysis Market Overview** ### **US Gene Expression Analysis Market Size and Growth** As per MRFR analysis, the US Gene Expression Analysis Market Size was estimated at 1.2 (USD Billion) in 2023. The US Gene Expression Analysis Market Industry is expected to grow from 1.5 (USD Billion) in 2024 to 4.5 (USD Billion) by 2035. The US Gene Expression Analysis Market CAGR (growth rate) is expected to be around 10.503% during the forecast period (2025 - 2035). ### **Key US Gene Expression Analysis Market Trends Highlighted** The US Gene Expression Analysis Market has been significantly influenced by several key market drivers. The increasing prevalence of genetic disorders and chronic diseases has heightened the demand for genomic research as a means to develop targeted therapies. Furthermore, the advancement of technologies such as next-generation sequencing and real-time PCR has made gene expression analysis more accessible and cost-effective for researchers in both academic and clinical settings. There are numerous opportunities to be captured within the US market, particularly with the ongoing growth in personalized medicine and companion diagnostics. The US government is actively promoting initiatives to boost genomic research and precision medicine, resulting in federal funding and support for academic and private sector collaborations. Additionally, the rise of bioinformatics tools and software has opened new avenues for the analysis and interpretation of gene expression data, making it easier for scientists to derive meaningful insights from complex genetic information. Trends in recent times indicate a shift towards integrating gene expression analysis with other omics technologies, such as proteomics and metabolomics, to provide a more comprehensive understanding of biological processes. This integrated approach is driving innovations in research methodologies and enhancing the overall accuracy of gene expression analysis. Additionally, there has been a rise in public awareness of genetic testing and its implications, further propelling interest in gene expression studies in the US. As healthcare continues to evolve, the demand for research in gene expression analysis is expected to grow, paving the way for innovative solutions and advancements in medical science. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Gene Expression Analysis Market Drivers** ### **Rising Prevalence of Chronic Diseases** The increasing prevalence of chronic diseases, particularly cancer and cardiovascular diseases, is a major driver for the US [Gene Expression Analysis Market](../../../reports/gene-expression-analysis-market-7805) Industry. According to the Centers for Disease Control and Prevention, chronic diseases affect approximately 60% of adults in the United States, leading to an increased demand for advanced diagnostic techniques such as gene expression analysis. The American Cancer Society reports that in 2020, approximately 1.8 million new cancer cases were diagnosed in the US, emphasizing the critical need for effective diagnostic tools and personalized treatment plans. Notable organizations like the National Institutes of Health and the American Society of Clinical Oncology are actively promoting gene expression studies to enable early detection and tailored therapies, thus significantly bolstering the growth of the US Gene Expression Analysis Market. ### **Advancements in Biotechnology** Advancements in biotechnology are significantly propelling the US Gene Expression Analysis Market Industry. Technological innovations, such as next-generation sequencing, have revolutionized gene expression profiling capabilities, allowing researchers and healthcare providers to obtain more accurate and comprehensive data. A report from the National Human Genome Research Institute highlights that the cost of sequencing a human genome has dropped from nearly $100 million in the early 2000s to around $1,000 today. This affordability increases access for research institutions and clinical laboratories, promoting the adoption of gene expression analysis technologies across the United States. ### **Government Initiatives and Funding** Government initiatives and funding in the field of genomic research significantly enhance the growth of the US Gene Expression Analysis Market Industry. The National Institutes of Health has invested over $1 billion annually in genomics research, which includes funding for gene expression studies. This commitment facilitates research that accelerates innovation in diagnostic and therapeutic approaches. Furthermore, programs such as the Precision Medicine Initiative aim to promote personalized treatment strategies, thus generating considerable momentum for gene expression analysis applications within the US. ## **US Gene Expression Analysis Market Segment Insights** ### **Gene Expression Analysis Market End-User Insights** The End-User segment of the US Gene Expression Analysis Market plays a crucial role in the overall landscape of genetic research and biotechnology. Pharmaceutical and Biotechnology Companies are at the forefront of this market, as they leverage gene expression analysis to facilitate drug discovery, development, and personalized medicine. By harnessing data from gene expression studies, these companies can identify molecular targets and understand the mechanisms of disease, ultimately leading to more effective therapeutic interventions. Academic and Research Institutes significantly contribute to the advancement of gene expression technologies, often leading groundbreaking studies that stimulate further exploration in genomics. Their focus on fundamental research aids in discovering new biomarkers and therapeutic targets, thus driving innovation within the industry. Contract Research Organizations (CROs) also serve an essential function by providing outsourced research services to pharmaceutical and biotechnology companies, enhancing efficiency and helping these organizations bring products to market more swiftly. CROs harness extensive expertise in gene expression analysis to assist various clients in navigating complex regulatory landscapes. The presence of regulatory compliance and quality assurance in these organizations adds credibility to the results obtained from gene expression studies, ensuring that data reliability is upheld. Other entities within the End-User segment, which may include diagnostic companies or regulatory bodies, also play a vital role in the ecosystem, further complicating and enriching the market dynamics. Each of these segments demonstrates unique characteristics that influence the US Gene Expression Analysis Market statistics, illustrating a rich tapestry woven from diverse applications such as clinical research, diagnostics, and biomanufacturing. As the market continues to expand, propelled by advancements in technology, rising investments in genomics, and an evolving understanding of genetic bases of diseases, the importance of each user segment will likely become more pronounced, shaping the future trajectory of the industry. This growth is supported by a strong infrastructure for Research and Development in the US, backed by significant federal funding and the presence of various competitive stakeholders. The confluence of these segments showcases a vibrant marketplace that is pivotal for future advancements in human health and disease management. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Gene Expression Analysis Market Product Insights** The Product segment of the US Gene Expression Analysis Market plays a pivotal role in driving advancements in biotechnology and personalized medicine. Within this segment, the focus on Consumables and Instruments is particularly significant. Consumables typically include reagents and kits essential for conducting gene expression analyses, supporting a wide array of applications from basic research to clinical diagnostics. These components are crucial due to their direct impact on the accuracy and efficiency of experiments. Instruments, on the other hand, embody sophisticated technologies like microarray and sequencing systems that enable high-throughput analysis, thereby facilitating extensive research and development activities in both academic and commercial settings. The demand for innovative and efficient instruments is continuously rising, as they are integral to improving the throughput and simplicity of genomic data generation. The overall growth in the US Gene Expression Analysis Market is fueled by advancements in technology, the increasing prevalence of chronic diseases, and the push for precision medicine. As a result, both Consumables and Instruments continue to evolve, offering substantial opportunities for growth and innovation within the market landscape. ### **Gene Expression Analysis Market Application Insights** The US Gene Expression Analysis Market, particularly in the Application segment, plays a pivotal role in revolutionizing healthcare and biological research. Within this domain, Drug Discovery is essential for identifying potential therapeutic targets, leading to the development of novel treatments. Diagnosis, as another critical aspect, utilizes gene expression data to enable precise disease identification and prognosis, particularly in oncology and genetic disorders. Furthermore, the Research application significantly contributes to understanding complex biological processes and disease mechanisms, promoting the development of innovative diagnostic tools and therapeutic strategies. With an increasingly data-driven focus in the US healthcare system, trends indicate a growing investment in gene expression technologies, supported by funding from various federal agencies. The market landscape is shaped by the rising prevalence of genetic disorders and the need for personalized medicine, making it a significant area of focus for future advancements. In addition, as more research institutions emphasize the importance of genetic analysis, this segment is expected to dominate the market, reflecting its integral role in driving scientific discovery and improving patient outcomes in the US. ### **Gene Expression Analysis Market Service Insights** The US Gene Expression Analysis Market is experiencing notable growth, particularly within the Service segment, which plays a critical role in advancing genomic research and personalized medicine. Gene Expression Profiling Services are crucial for understanding cellular processes, allowing researchers to identify the underlying mechanisms of diseases and refine therapeutic approaches. Sequencing Services contribute significantly by providing precise and comprehensive insights into genetic variations, thereby facilitating innovations in diagnostics and treatment strategies. Bioinformatics Solutions are increasingly vital in this landscape, as they enable the analysis and interpretation of complex biological data, leading to actionable findings in clinical research and drug development. The diversity of services available highlights the market's adaptability and responsiveness to evolving scientific demands. Overall, this segment is central to the wider US Gene Expression Analysis Market, addressing the increasing need for sophisticated solutions in various applications ranging from research and academic institutions to clinical laboratories and biopharmaceutical companies, all of which are striving to enhance their capabilities in gene analysis and project outcomes. ## **US Gene Expression Analysis Market Key Players and Competitive Insights** The US Gene Expression Analysis Market is characterized by rapid advancements and competitive dynamics that reflect the growing importance of genomics in biomedical research, diagnostics, and personalized medicine. A diverse range of companies and research institutions are involved in this market, leveraging technologies such as microarray, qPCR, and next-generation sequencing to contribute to a deeper understanding of gene expression patterns. As research funding increases and the demand for faster, more accurate diagnostic tools grows, companies within this market continually innovate to maintain or expand their market presence. Furthermore, collaborations between academic institutions and private companies have fostered a fertile environment for innovation and growth, ensuring that advancements in gene expression analysis remain at the forefront of scientific inquiry and application. Illumina stands out in the US Gene Expression Analysis Market due to its substantial market presence and comprehensive product offerings. The company has established itself as a leader through its innovative sequencing technologies, which are pivotal for analyzing complex gene expression landscapes. Illumina's strengths lie in its advanced platforms and tools, which facilitate high-throughput sequencing and robust data analysis capabilities. This positions Illumina favorably as researchers and institutions increasingly seek to leverage genomic insights in various applications, from cancer research to hereditary disease studies. The company’s commitment to ongoing R&D ensures continual improvement of its product portfolio, enhancing performance, accuracy, and usability in gene expression analysis, thereby solidifying its competitive edge within the market. Expression Analysis represents a significant player in the US market for Gene Expression Analysis by providing dedicated services that focus on gene expression profiling and genomic data interpretation. The company offers advanced solutions, including microarray analysis, RNA sequencing, and bioinformatics support, allowing researchers to derive actionable insights from their gene expression data. With a robust presence in the US, Expression Analysis capitalizes on strong relationships with academic institutions and clinical research organizations. The company is known for its strengths in delivering customized analysis tailored to specific research needs, which has allowed it to build a loyal customer base. Furthermore, strategic mergers and acquisitions have enhanced its capabilities and expanded its portfolio, enabling it to stay competitive in the rapidly evolving landscape of gene expression analysis. Overall, Expression Analysis continues to strengthen its position through innovation and customer-focused service offerings in the US market. ### **Key Companies in the US Gene Expression Analysis Market Include** ## **US Gene Expression Analysis Market Industry Developments** In recent months, the US Gene Expression Analysis Market has witnessed significant developments, particularly involving key players such as Illumina, Thermo Fisher Scientific, and BioRad Laboratories. Illumina announced the release of a groundbreaking technology in September 2023 aimed at enhancing the accuracy of gene expression profiling. Additionally, in August 2023, Thermo Fisher Scientific expanded its product portfolio through the acquisition of a specialized biotechnology firm focused on RNA sequencing tools, signaling a strategic move to strengthen its market position. BioRad Laboratories introduced a new set of qPCR reagents, which have been well-received in the research community. The market valuation for companies engaged in gene expression analysis has shown substantial growth, attributed to increasing demand in genomics and personalized medicine, driven by advancements in biotechnology. Over the past years, significant industry collaborations have been noted, including Novogene's partnership with prominent academic institutions in June 2022 to advance cancer research using gene expression technologies. Furthermore, companies such as Qiagen are focusing on integrating artificial intelligence to enhance data analysis capabilities, underscoring the ongoing trend toward innovation and efficiency in the US Gene Expression Analysis sector. ## **US Gene Expression Analysis Market Segmentation Insights** ### **Gene Expression Analysis Market End-User Outlook** ### **Gene Expression Analysis Market Product Outlook** ### **Gene Expression Analysis Market Application Outlook** ### **Gene Expression Analysis Market Service Outlook** ## Market Drivers ### Advancements in Genomic Technologies Technological innovations in genomic sequencing and analysis are significantly influencing the gene expression-analysis market. The advent of next-generation sequencing (NGS) technologies has revolutionized the way gene expression data is collected and analyzed. These advancements have led to a reduction in costs, with sequencing prices dropping by over 90% in the last decade. As a result, researchers and clinicians are increasingly adopting these technologies to gain insights into gene expression patterns. The gene expression-analysis market is expected to benefit from the proliferation of high-throughput sequencing methods, which allow for the simultaneous analysis of thousands of genes. This trend not only enhances the efficiency of research but also accelerates the pace of discoveries in genomics, thereby driving market growth. ### Rising Demand for Precision Medicine The increasing emphasis on precision medicine is a pivotal driver for the gene expression-analysis market. As healthcare shifts towards more personalized treatment approaches, the need for accurate gene expression data becomes paramount. This market is projected to grow at a CAGR of approximately 10% from 2025 to 2030, reflecting the rising demand for tailored therapies. Healthcare providers and researchers are increasingly relying on gene expression analysis to identify biomarkers and develop targeted treatments, thereby enhancing patient outcomes. The integration of gene expression data into clinical workflows is expected to streamline the drug development process, making it more efficient and cost-effective. Consequently, The gene expression analysis market is likely to experience substantial growth. ### Growing Awareness of Genetic Disorders The rising awareness of genetic disorders among the general public and healthcare professionals is propelling the gene expression-analysis market forward. As more individuals seek genetic testing and counseling, the demand for comprehensive gene expression analysis increases. Educational campaigns and initiatives by health organizations have contributed to a better understanding of the implications of genetic variations on health. This heightened awareness is leading to an increase in diagnostic testing, which often incorporates gene expression analysis to provide insights into disease predisposition and treatment options. Consequently, The gene expression analysis market is poised for growth. ### Increased Funding for Genomic Research The gene expression analysis market is experiencing a surge in funding. Government initiatives and grants aimed at advancing genomic research have increased significantly, with funding levels reaching approximately $1.5 billion in 2025. This financial support is directed towards innovative research projects that utilize gene expression analysis to explore various diseases, including cancer and genetic disorders. The influx of capital enables researchers to access advanced technologies and methodologies, thereby enhancing the quality and scope of their studies. As funding continues to rise, the gene expression-analysis market is likely to expand, fostering an environment conducive to groundbreaking discoveries and advancements in the field. ### Collaborations Between Academia and Industry Collaborative efforts between academic institutions and industry players are emerging as a significant driver for the gene expression-analysis market. These partnerships facilitate the exchange of knowledge, resources, and technologies, ultimately accelerating research and development in the field. By pooling expertise, both sectors can address complex challenges in gene expression analysis, leading to innovative solutions and products. Such collaborations often result in the commercialization of research findings, which can enhance the availability of advanced gene expression analysis tools and services. As these partnerships continue to flourish, the gene expression-analysis market is likely to benefit from increased innovation and a more robust pipeline of products, thereby meeting the growing demands of researchers and clinicians. ## Future Outlook The [Gene Expression Analysis Market](https://www.marketresearchfuture.com/reports/gene-expression-analysis-market-7805) is projected to grow at a 10.31% CAGR from 2025 to 2035, driven by advancements in biotechnology, increasing research funding, and rising demand for personalized medicine. **New opportunities:** - Development of AI-driven gene expression analysis software solutions. Expansion of gene expression profiling services for clinical trials. Partnerships with biotech firms for co-development of novel therapeutics. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in biotechnology. ## Segment Insights ### By End User: Pharmaceutical & Biotechnology Companies (Largest) vs. Academic & Research Institutes (Fastest-Growing) In the US gene expression-analysis market, the distribution of market share among end users is primarily led by Pharmaceutical & Biotechnology Companies, which dominate the segment due to their extensive research and development activities. Close behind is the Academic & Research Institutes segment, which although smaller in market share, plays a pivotal role in advancing gene expression analysis through innovative research and collaborations with industry. Growth trends in this segment are driven by increasing investments in biopharmaceutical research and a surge in genetic research initiatives. The demand for advanced gene expression tools in pharmaceuticals is expanding, as companies seek to innovate and expedite drug development processes. Academic institutions are also increasingly leveraging these technologies, contributing to the growth of the segment by educating future scientists and conducting groundbreaking research. Pharmaceutical & Biotechnology Companies: Dominant vs. Academic & Research Institutes: Emerging Pharmaceutical & Biotechnology Companies are positioned as the dominant force in the US gene expression-analysis market due to their ability to invest heavily in research activities and cutting-edge technologies that enhance drug discovery and development. This segment benefits from established infrastructures and regulatory frameworks, allowing for rapid advancements in therapeutic solutions. On the other hand, Academic & Research Institutes represent the emerging segment that fuels innovation and research collaboration. They are critical for training new researchers and conducting pioneering studies that often lead to partnerships with biotech firms. The growth in this sphere is propelled by increasing funding for genetic research and a broader access to advanced tools, making them vital players in the overall landscape. ### By Product: Consumables (Largest) vs. Instruments (Fastest-Growing) In the US gene expression-analysis market, consumables hold the largest market share, driven by their essential role in various experiments and research applications. Consumables such as reagents, kits, and assays are crucial for performing gene expression tests, leading to their dominance in this segment. Instruments, while smaller in share, are rapidly gaining traction due to the continuous advancements in technology and the increasing demand for automation and precision in gene analysis. Growth trends in this segment highlight a shift towards more sophisticated instruments that can provide faster and more accurate results. The rise in personalized medicine and genomics research is amplifying the need for advanced instruments, marking them as the fastest-growing category in the US gene expression-analysis market. This growth is fueled by technological innovations and the increasing importance of gene expression data in clinical settings. Consumables: Dominant vs. Instruments: Emerging Consumables are the backbone of the US gene expression-analysis market, providing the necessary materials for various analytical procedures. Their dominance stems from the widespread use of assays, reagents, and kits across laboratories and research institutions. Their reliability and ease of use make them a preferred choice among researchers. On the other hand, instruments are emerging segments that are gaining popularity due to the latest technological advancements. These include high-throughput sequencers and real-time PCR devices, which enhance the efficiency and accuracy of gene expression analyses. As research demands evolve, instruments are becoming more sophisticated, driving their rapid growth and increasing market relevance. ### By Application: Drug Discovery (Largest) vs. Research (Fastest-Growing) In the US gene expression-analysis market, Drug Discovery accounts for the largest share, reflecting its critical role in the development of new therapeutics. This segment is heavily utilized by pharmaceutical companies to elucidate the mechanisms of diseases and to identify potential drug targets, thus dominating the market landscape. On the other hand, other applications such as Diagnosis and Research are making significant strides, contributing to the overall competitive dynamics of the market. The growth trends in the application segment are propelled by advancements in technology and increasing investments in research and development. The rise in precision medicine and personalized therapies also bolsters the demand for gene expression analysis, especially in the Research segment, which is identified as the fastest-growing area. As researchers strive to gain deeper insights into gene functions, the application of gene expression tools in various scientific studies is expected to surge, enhancing market prospects further. Research (Dominant) vs. Diagnosis (Emerging) Research plays a dominant role in the US gene expression-analysis market, driven by a robust focus on innovative scientific exploration and understanding complex biological processes. It encompasses a wide range of studies across academic and commercial laboratories, making it integral to expanding the knowledge base in genomics. In comparison, the Diagnosis segment is emerging as a key player, particularly as advancements in gene expression analysis enable more accurate and timely identification of diseases. This segment is increasingly being integrated into routine clinical practices, indicating a shift towards personalized healthcare. The juxtaposition of these segments highlights the strong foundational support of Research which fuels the evolving diagnostic applications, marking a collaborative growth trajectory. ### By Service: Gene Expression Profiling Services (Largest) vs. Sequencing Services (Fastest-Growing) Within the service segment of the US gene expression-analysis market, Gene Expression Profiling Services hold the largest market share, driven by their essential role in identifying gene expressions across various diseases and conditions. Sequencing Services, while not dominating the market, are rapidly gaining traction, contributing significantly to the overall growth of this sector. Both services cater to a variety of research and clinical applications, reflecting the increasing demand for precise gene analysis in personalized medicine. The growth trends in this segment are influenced by advancements in technology, which enhance the accuracy and efficiency of gene expression analyses. The rising prevalence of genetic disorders and the subsequent need for diagnostic clarity are primary growth drivers. Furthermore, increased investments in biotechnology and genomics research are also propelling the demand for these services, particularly in bioinformatics solutions that complement sequencing capabilities. Gene Expression Profiling Services (Dominant) vs. Sequencing Services (Emerging) Gene Expression Profiling Services are characterized by their comprehensive approach to analyzing gene expression levels, making them integral to research and clinical settings. This service type has established a dominant position due to its extensive applications in understanding diseases, drug development, and personalized medicine. In contrast, Sequencing Services are emerging rapidly as technological advancements lower costs and expand accessibility, making genomic analyses more feasible for various institutions. While Gene Expression Profiling Services are recognized for yielding crucial insights in gene regulation and expression patterns, Sequencing Services are becoming increasingly popular for their ability to provide deeper genomic information, thereby enriching the overall gene analysis ecosystem. ## Competitive Benchmarking The gene expression-analysis market is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for personalized medicine. Key players such as Thermo Fisher Scientific (US), Illumina (US), and Agilent Technologies (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Thermo Fisher Scientific (US) focuses on expanding its product portfolio through continuous innovation, while Illumina (US) emphasizes its leadership in next-generation sequencing technologies. Agilent Technologies (US) adopts a strategy centered on integrating advanced analytics into its offerings, thereby enhancing the value proposition for its customers. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and customer-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a diverse range of products and services, catering to various customer needs while fostering competition among established and emerging players. In October Thermo Fisher Scientific (US) announced the launch of a new suite of gene expression analysis tools designed to streamline workflows and improve data accuracy. This strategic move is likely to enhance the company's competitive edge by addressing the growing demand for high-throughput solutions in research and clinical applications. By investing in innovative technologies, Thermo Fisher Scientific (US) positions itself as a leader in the market, potentially increasing its market share. In September Illumina (US) entered into a partnership with a leading biotechnology firm to develop a novel gene expression profiling platform. This collaboration is expected to accelerate the development of personalized therapies, aligning with the industry's shift towards precision medicine. Such strategic alliances not only enhance Illumina's technological capabilities but also expand its reach within the healthcare ecosystem, thereby reinforcing its competitive position. In August Agilent Technologies (US) acquired a small biotech company specializing in RNA sequencing technologies. This acquisition is indicative of Agilent's commitment to enhancing its product offerings and expanding its capabilities in gene expression analysis. By integrating advanced RNA sequencing technologies, Agilent Technologies (US) is likely to strengthen its market presence and provide customers with cutting-edge solutions that meet evolving research demands. As of November current trends in the gene expression-analysis market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) into research workflows. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a greater emphasis on technological innovation, reliability in supply chains, and the ability to deliver personalized solutions. This transition underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the market. ## Recent News & Developments In recent months, the US Gene Expression Analysis Market has witnessed significant developments, particularly involving key players such as Illumina, Thermo Fisher Scientific, and BioRad Laboratories. Illumina announced the release of a groundbreaking technology in September 2023 aimed at enhancing the accuracy of gene expression profiling. Additionally, in August 2023, Thermo Fisher Scientific expanded its product portfolio through the acquisition of a specialized biotechnology firm focused on RNA sequencing tools, signaling a strategic move to strengthen its market position. BioRad Laboratories introduced a new set of qPCR reagents, which have been well-received in the research community. The market valuation for companies engaged in gene expression analysis has shown substantial growth, attributed to increasing demand in genomics and personalized medicine, driven by advancements in biotechnology. Over the past years, significant industry collaborations have been noted, including Novogene's partnership with prominent academic institutions in June 2022 to advance cancer research using gene expression technologies. Furthermore, companies such as Qiagen are focusing on integrating artificial intelligence to enhance data analysis capabilities, underscoring the ongoing trend toward innovation and efficiency in the US Gene Expression Analysis Market sector. ## Report Scope | MARKET SIZE 2024 | 1140.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1257.53(USD Million) | | MARKET SIZE 2035 | 3356.2(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.31% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Illumina (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Qiagen (DE), Roche (CH), PerkinElmer (US), Merck KGaA (DE), Takara Bio (JP) | | Segments Covered | End User, Product, Application, Service | | Key Market Opportunities | Advancements in single-cell sequencing technologies enhance precision in the gene expression-analysis market. | | Key Market Dynamics | Technological advancements drive innovation in gene expression analysis, enhancing research capabilities and competitive positioning. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US gene expression-analysis market in 2024?** A: The market valuation was $1140.0 Million in 2024. **Q: What is the projected market valuation for the US gene expression-analysis market by 2035?** A: The projected valuation for 2035 is $3356.2 Million. **Q: What is the expected CAGR for the US gene expression-analysis market during the forecast period 2025 - 2035?** A: The expected CAGR is 10.31% during the forecast period 2025 - 2035. **Q: Which segments contributed to the US gene expression-analysis market in 2024?** A: Key segments included Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations. **Q: What was the valuation of the consumables segment in the US gene expression-analysis market in 2024?** A: The consumables segment was valued at $600.0 Million in 2024. **Q: How much is the instruments segment projected to be worth by 2035?** A: The instruments segment is projected to reach $1656.2 Million by 2035. **Q: What applications are driving growth in the US gene expression-analysis market?** A: Drug Discovery, Diagnosis, and Research are key applications driving growth. **Q: What was the valuation of sequencing services in the US gene expression-analysis market in 2024?** A: Sequencing services were valued at $450.0 Million in 2024. **Q: Who are the key players in the US gene expression-analysis market?** A: Key players include Thermo Fisher Scientific, Illumina, Agilent Technologies, and Bio-Rad Laboratories. **Q: What is the projected growth for the gene expression profiling services segment by 2035?** A: The gene expression profiling services segment is projected to reach $850.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-gene-expression-analysis-market-19653*